HHO Insert: Below is a recent article that will show a significant value in some of the "other cannabinoids" that make up the available “spectrum”, and may help you understand the terms used to describe Cannabis products a bit better. To prepare you for this topic, here are some observations that we've made with clients in our Healthy Hemp Outlet CBD Store in St. Petersburg, FL.
Clients come in and ask if our cbd oil is Full Spectrum? We have COA Lab reports to share and while doing so it is obvious to see that the SPECTRUM OF AVAILABLE CANNABINOIDS on the test do Mostly show a good % score for CBD (after all that is what you are paying for), but if you notice the other cannabinoids like CBC and CBG - you may notice a result like: ND, 0.00% or it may not be on the COA Lab report at all.
In 2011, Dr. Ethan Russo published an article in the British Journal of Pharmacology suggesting that cannabinoids have a synergistic effect. In a nutshell, this means that they work better together rather than as isolates by themselves. He coined this effect as the ‘entourage effect.’
Some users prefer full-spectrum products because they can trigger the entourage effect. With multiple cannabinoids and terpenes working together, the results and benefits experienced may be greater than the results of a CBD isolate. Terpenes are believed to play a significant role in the entourage effect – perhaps even more so than cannabinoids!
So how does a Full Spectrum product actually not have a Full Spectrum? We believe this is an honest oversight made by the Cannabis Industry that must have started when Extractions became legal and popular. Our presumption is that a cannabis product that is called FULL SPECTRUM is more about the POTENTIAL for the product to have a FULL SPECTRUM. When the seed was planted it was intended to offer a Full Spectrum (straight A's on the report card), but when the extraction and PROCESSING is done, a few of the "other cannabinoids" are harmed or lost (so you get a lower grade in the other spectrums), and what started as a FULL SPECTRUM ends up being a "PARTIAL SPECTRUM".
You can look at it this way - pretend you are buying a Rainbow. A rainbow is a "spectrum of color", and there are (7) colors that make up a traditional rainbow. If the label on a Rainbow package said FULL SPECTRUM, but there was NO Yellow and only a .15% score of Green - well you're NOT going to see a Full rainbow because it is missing Yellow and you can barely see green - so you are really getting a “partial spectrum”?
This Point is made obvious by the two COA lab reports shown in this blog. One COA is for our HHO 900 and it is offered as a Full Spectrum Oil, it was C02 extracted - note it has a good score for CBD, but has 0.00% of CBG.
Please note this is the same as going to the drugstore and buying a bottle of vitamin C. You are buying one thing (Vitamin-C). When you hear the word full spectrum it’s comparable to the term multivitamin so you expect more from a multivitamin than you do when you buy just the one vitamin.
So when you are buying CBD and looking at a COA lab report it very well should represent a good CBD value - and IT IS COMMON for it to not show a value for the other cannabinoids because technically you’re not paying for them (buying CBD), or are you (marketed as Full Spectrum)?
Then Notice our 900 PLUS version. It was extracted using the Distillate method, and it has CBD +PLUS +CBG +PLUS +CBC. It is still not a FULL Spectrum (literally), but is has a more complete cannabinoid profile - so it is a FULLER Spectrum.
Here is the original article from Yahoo finance with full credit given to the author. Our goal here was to educate you on the Term Full Spectrum and know more about how to read a lab report.
Click image above to learn more about our 900+ which has CBC and CBG.
Cannabics Pharmaceuticals Study Shows Cannabinoids CBC and CBG Exhibit
Anti-Tumor Properties on Gastrointestinal Cancer Cells
, Israel and BETHESDA, Maryland, Jan. 27, 2020
/PRNewswire/ -- Cannabics Pharmaceuticals Inc.
(OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that in a series of tests conducted at the company's High Through-put Screening (HTS) facility in Israel
, it has been shown that the cannabinoids CBC (Cannabichromene) and CBG (Cannabigerol) both exhibit anti-tumor properties, tested on human Gastrointestinal Cancer Cells.
Cannabinoid extract causing necrosis in Gastrointestinal cancer cell line. The Yellow color is a marker for necrosis. On the right - control, on the left – after treatment with cannabinoids
CBC is an additional non-psychoactive cannabinoid and is one of the naturally occurring Phyto-cannabinoids. It bears a host of potential positive therapeutic qualities and may promote antimicrobial, anti‐inflammatory, analgesic, and neurogenesis activity. It is particularly found in younger Cannabis plants, albeit in small quantities.
In these tests, the HTS platform was utilized to screen the necrotic effects of a variety of cannabinoids on human Gastrointestinal cancer cells, in addition to other cancer types previously tested. CBC and CBG were both shown to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids, thus strengthening previously obtained results.
Dr. Yaakov Waksman, the company's head of cannabidiol research, said, "My working assumption is that these results show that a correlation may exist between a cannabinoid's Topological Polar Surface Area (TPSA) value and its ability to induce anti-tumor activity, diminishing cancer cell's viability rates. CBC and CBG, as neutral cannabinoids, were both found to have a TPSA value which allows the cannabinoid molecule to penetrate a cancer cell's membrane, whereas their acidic form (CBCA and CBGA) - do not. This could explain the difference in anti-tumor activity rates demonstrated".
Dr. Eyal Ballan, CTO and Co-Founder, commented, "Gastrointestinal cancers are amongst the leading and most wide-spread causes of cancer-related deaths worldwide. We are intrigued by the results we have obtained in the lab, and our aim is to consider placing an emphasis on this organ system, and to further explore the differential anti-tumor properties of cannabinoids. We believe that these preliminary results vindicate our vision; which is to bring personalization into cannabinoid-based cancer treatments."
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For more information, please visit www.cannabics.com
For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter@Cannabics, Facebook@CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed January 14th, 2020. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its source.